Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys and Copegus Duration in HCV Genotype 1
NCT00336518Phase 3Unknown
- Sponsor
- Májbetegekért Alapítvány
- Start
- Jun 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Májbetegekért Alapítvány. Primary endpoint: Sustained Viral Response. Status: unknown.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00336518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336518.